All In Biotech

Drug Trial Radar · NCT05297201

Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia

Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A Inhibitor) in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesia

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

105

Actual

Start

Nov 2, 2021

Primary completion

Jan 13, 2025

Study completion Jan 27, 2025

Sponsor

Lead sponsor
Celon Pharma SAIndustry
Sponsor type
Industry
Collaborators
National Center for Research and Development, Poland
First posted
Mar 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia. The study is to determine the efficacy and dose response of two CPL500036 doses, compared with placebo.

Conditions

  • Parkinson Disease
  • Dyskinesia, Medication-Induced

Interventions

  • CPL500036 - low doseDrug

    CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.

  • CPL500036 - high doseDrug

    CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.

  • PlaceboDrug

    Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total UDysRS Score at Week 4.Time frame: Day -1, Day 28

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Instytut Zdrowia dr Boczarska-Jedynak Sp. Z o.o., Sp. K.,

    Oświęcim, Małopolska, Poland

  • Mazowiecki Szpital Bródnowski

    Warsaw, Masovian Voivodeship, Poland

  • Cherkasy Regional Hospital of the Cherkasy Regional Council

    Cherkasy, Ukraine

  • Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Department of Neurology and Borderline Conditions;

    Dnipro, Ukraine

  • Treatment and Diagnostic Centre "Neuro Global" of the Limited Liability Company "Neuro Global", Treatment and Prevention Sub-division

    Ivano-Frankivsk, Ukraine

  • Institute of Neurology, Psychiatry and Narcology of the Academy of Medical Sciences of Ukraine, Department of Vascular Pathology of the Brain and Rehabilitation

    Kharkiv, Ukraine

  • "Medical center "Dobrobut-Polyclinic" "Medical diagnostic center "Dobrobut"

    Kyiv, Ukraine

  • Medical Center of the Limited Liability Company "Medical Center "Consilium Medical"

    Kyiv, Ukraine

  • "D.F. Chebotaryov Institute of Gerontology of the National Academy of Medical Sciences of Ukraine

    Kyiv, Ukraine

  • Municipal non-profit enterprise of Lviv regional council "Lviv regional clinical hospital", Neurological Department

    Lviv, Ukraine

  • Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of the Poltava Regional Council

    Poltava, Ukraine

  • Limited Liability Company, Medical Center "DIAMED"

    Uzhhorod, Ukraine

  • Medical Center of the Limited Liability Company "Salyutem Medical Center"

    Vinnytsy, Ukraine

  • "INET-09" LLC (Medical Center)

    Zaporizhzhya, Ukraine

  • Educational and Scientific Medical Center "University Clinic" of Zaporizhzhia State Medical University

    Zaporizhzhya, Ukraine

  • Communal Enterprise "Hospital" of Zhytomyr City Council

    Zhytomyr, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.